Úc - Tiếng Anh - APVMA (Australian Pesticides and Veterinary Medicines Authority)

oz crop pty ltd - azoxystrobin; cyproconazole - water dispersible granule - azoxystrobin pyrimidine active 600.0 g/kg; cyproconazole triazole active 240.0 g/kg - fungicide

Úc - Tiếng Anh - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - carfentrazone-ethyl; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - carfentrazone-ethyl ungrouped active 400.0 g/l; n-methyl-2-pyrrolidone solvent other 100.0 g/l; liquid hydrocarbon solvent other 452.0 g/l - herbicide

Úc - Tiếng Anh - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - propiconazole; liquid hydrocarbon - emulsifiable concentrate - propiconazole triazole active 550.0 g/l; liquid hydrocarbon solvent other 371.0 g/l - fungicide

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet, uncoated - excipient ingredients: purified talc; citric acid monohydrate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; maize starch; stearic acid - pharmacor rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; stearic acid; purified talc; citric acid monohydrate; maize starch - akm rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet, uncoated - excipient ingredients: purified talc; colloidal anhydrous silica; pregelatinised maize starch; maize starch; stearic acid; microcrystalline cellulose; citric acid monohydrate - akm rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; stearic acid; citric acid monohydrate; purified talc; maize starch; microcrystalline cellulose; pregelatinised maize starch - pharmacor rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Israel - Tiếng Anh - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - capsules - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.

Israel - Tiếng Anh - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - capsules - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.

Israel - Tiếng Anh - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - capsules - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.